KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.Nat CommunPMID 39261482PMC113909392024-Sep-110.98未发现恶性肿瘤人群证据。待处理
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.J Clin OncolPMID 39018515PMC113793572024-Sep-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome.J Am Coll CardiolPMID 39232634无 PMCID2024-Sep-100.98未发现恶性肿瘤人群证据。待处理
Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis.Acta Derm VenereolPMID 39248292PMC114033642024-Sep-090.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial.BMC Palliat CarePMID 39244530PMC113807732024-Sep-070.93干预为非药物单独策略,未满足药物干预要求。待处理
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).Arthritis Res TherPMID 39244595PMC113803392024-Sep-070.98未发现恶性肿瘤人群证据。待处理
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.OncologistPMID 38748596PMC113796362024-Sep-060.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.Neuro OncolPMID 38502052PMC113764482024-Sep-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.BloodPMID 38754046PMC114061682024-Sep-050.85This is a descriptive analysis of mutational profiles and clonal evolution in patients with CLL progression on BTK inhibitors. It is not a report of a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, KM, HR).待处理
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.N Engl J MedPMID 39231341无 PMCID2024-Sep-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.N Engl J MedPMID 39231343PMC115283492024-Sep-050.98未发现恶性肿瘤人群证据。待处理
Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.Acta Derm VenereolPMID 39233617PMC113881052024-Sep-050.98未发现恶性肿瘤人群证据。待处理
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.Antimicrob Agents ChemotherPMID 39082883PMC113732262024-Sep-040.98未发现恶性肿瘤人群证据。待处理
Quantitative comparison of automated OCT and conventional FAF-based geographic atrophy measurements in the phase 3 OAKS/DERBY trials.Sci RepPMID 39227682PMC113720552024-Sep-040.98未发现恶性肿瘤人群证据。待处理
Exercise and QUality Diet after Leukemia: A Randomized Weight Loss Trial among Adult Survivors of Childhood Leukemia in the Childhood Cancer Survivor Study.Cancer Epidemiol Biomarkers PrevPMID 38652494PMC113715362024-Sep-030.95The study is an oncology randomized trial with original results, but it does not meet the required criteria: the primary endpoint is weight change (a continuous measure), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). Additionally, the intervention is a behavioral/lifestyle program (exercise and diet), not a drug-containing intervention.待处理
Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis.RMD OpenPMID 39231546PMC114093512024-Sep-030.98未发现恶性肿瘤人群证据。待处理
Iloprost and Organ Dysfunction in Adults With Septic Shock and Endotheliopathy: A Randomized Clinical Trial.JAMA Netw OpenPMID 39259541PMC113913232024-Sep-030.98未发现恶性肿瘤人群证据。待处理
Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study.CorneaPMID 37921522PMC112962762024-Sep-010.98未发现恶性肿瘤人群证据。待处理
Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.J Clin GastroenterolPMID 38019088PMC113056202024-Sep-010.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.J Clin OncolPMID 38564700无 PMCID2024-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.Rheumatology (Oxford)PMID 38754125PMC113713722024-Sep-010.98未发现恶性肿瘤人群证据。待处理
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer.J Clin OncolPMID 38833643PMC115654892024-Sep-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.Endocr Relat CancerPMID 38913539PMC113014212024-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial.JAMA CardiolPMID 38958989PMC112230442024-Sep-010.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.J Clin OncolPMID 38996201无 PMCID2024-Sep-011.00命中用户提供的消化道肿瘤阳性参考集。待处理
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial.JAMA DermatolPMID 39083288PMC112925732024-Sep-010.98未发现恶性肿瘤人群证据。待处理
Post Hoc Analysis Comparing the Safety and Efficacy of PrabotulinumtoxinA in Millennials and Nonmillennials With Moderate to Severe Glabellar Lines.Dermatol SurgPMID 39196832无 PMCID2024-Sep-010.98未发现恶性肿瘤人群证据。待处理
Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomized Clinical Trial.Asian Pac J Cancer PrevPMID 39342581PMC117003052024-Sep-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.Clin J Am Soc NephrolPMID 40179340PMC113900312024-Sep-010.98未发现恶性肿瘤人群证据。待处理
Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.J Diabetes InvestigPMID 38794986PMC113631132024-Sep0.98未发现恶性肿瘤人群证据。待处理
Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial.Diabetes Metab JPMID 38310875PMC114498222024-Sep0.98未发现恶性肿瘤人群证据。待处理
The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial.Am J TransplantPMID 38387622无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Randomized controlled trial of remimazolam compared with placebo in Japanese patients undergoing upper gastrointestinal endoscopy: Phase III investigator-initiated clinical trial.Dig EndoscPMID 38403959无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study.OphthalmologyPMID 38423215无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension.OphthalmologyPMID 38423216无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.Prostate Cancer Prostatic DisPMID 38424319PMC120368202024-Sep0.85This is a pre-planned subset analysis of a Phase III randomized trial, not the primary or key secondary efficacy report of the trial itself. While it reports on OS, the focus is on biomarker prognostic value within a subset, not the primary comparison of drug interventions.待处理
Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment.Eur J Intern MedPMID 38521730无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.J Formos Med AssocPMID 38548524无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Comparing the latent state-trait structure of the PANSS in cariprazine-medicated and placebo-controlled patients with acute schizophrenia.Eur Arch Psychiatry Clin NeurosciPMID 38553640PMC113621892024-Sep0.98未发现恶性肿瘤人群证据。待处理
Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis.Clin Pharmacol TherPMID 38627914无 PMCID2024-Sep0.85The record describes a non-oncology disease (ulcerative colitis), reports on a Phase 2b trial used to model predictions for a future Phase 3 study, and does not report any time-to-event efficacy endpoints (Kaplan-Meier or HR).待处理
Pharmacokinetics of Edoxaban 15 mg in Very Elderly Patients with Nonvalvular Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Study.Thromb HaemostPMID 38641335PMC113494242024-Sep0.98未发现恶性肿瘤人群证据。待处理
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.J Am Acad DermatolPMID 38685404无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.Ann Allergy Asthma ImmunolPMID 38697286无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study.J Allergy Clin Immunol PractPMID 38777124无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.J Am Acad DermatolPMID 38777187无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.Eur J Nucl Med Mol ImagingPMID 38795120无 PMCID2024-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS.J Manag Care Spec PharmPMID 38807035PMC113658172024-Sep0.95The record describes a Phase III randomized trial of darolutamide in mHSPC with drug intervention, but the analysis is a health-economic and resource utilization study focusing on hospitalization rates and budget impact. It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curve, or HR) required for inclusion in the oncology Kaplan-Meier digitization cohort.待处理
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.Eur UrolPMID 38811313PMC120360812024-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.Nat MedPMID 38823511PMC114052672024-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center.JCO Oncol PractPMID 38848539无 PMCID2024-Sep0.85The study is an implementation science trial focused on medication safety with oral antitumor therapy. While it is an oncology, human, randomized, Phase III trial with a drug intervention and reports original results, it lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Its primary endpoint is an implementation outcome (percentage of patients counseled).待处理